Results 21 to 30 of about 203,196 (295)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Journal of Medical Case Reports, 2011
Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph, Kochanek Matthias, Nogova Lucia, Rothe Achim, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael   +5 more
doaj   +1 more source

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]

, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Bench, AJ, Campbell, LJ, Grace, C, Green, AR, Huntly, BJP, Nacheva, EP, Prince, HM, Reid, AG, Shepherd, P, Szer, J, Telford, N, Turner, P   +11 more
core   +1 more source

Comparative analysis of blood lymphocytes of patients with acute and chronic myeloid leukemia by surface and intracellular α1-acid glycoprotein and fibronectin

Біологічні студії, 2014
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

Haematologica, 2010
Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello, Federica Villanova, Veronica Tisato, Stefania Lymperi, Ka-Kei Ho, Ana R. Gomes, David Marin, Dominique Bonnet, Jane Apperley, Eric W.-F. Lam, Francesco Dazzi   +10 more
doaj   +1 more source

Bilateral vision loss as initial presentation of chronic myeloid leukemia in a young adult: A case report and review of the literature

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case of bilateral vision loss as the primary presenting symptom of chronic myeloid leukemia in a young adult. Observations: The 28-year-old male patient presented to clinic with visual acuity of 20/200 in both eyes after several ...
Nathan J. Brown, Erin A. Kaya, Jonathan G. Haymore, Lauren V. Gioia   +3 more
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin, Blatt, Katharina, Cerny-Reiterer, Sabine, Herndlhofer, Susanne, Herrmann, Harald, Hoermann, Grego, Holyoake, Tessa L., Mannhalter, Christine, Mayerhofer, Matthias, Rulicke, Thomas, Sadovnik, Irina, Sperr, Wolfgang R., Stefanzl, Gabriele, Streubel, Berthold, Valent, Peter, Willmann, Michael   +15 more
core   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj   +1 more source